SCHEMBL6705449

SCHEMBL6705449

CC(=O)OCC(C)CC(OC(C)=O)n1cnc2c(Cl)cc(N)nc21

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ ADRA1A P35348 1/20 0.33
▸ HSD17B10 Q99714 1/20 0.33
▸ RXFP1 Q9HBX9 1/20 0.33
▸ PDE8A O60658 3/20 0.32
▸ PDE2A O00408 1/20 0.32
▸ PDE4D Q08499 1/20 0.32
▸ KCNH2 Q12809 1/20 0.32
▸ PDE10A Q9Y233 1/20 0.32
▸ CDK1 P06493 2/20 0.30
▸ CDK2 P24941 2/20 0.30
▸ PRKACA P17612 1/20 0.30
▸ CCNA2 P20248 1/20 0.30
▸ PRKACG P22612 1/20 0.30
▸ PRKACB P22694 1/20 0.30
▸ MAPK3 P27361 1/20 0.30
▸ MAPK1 P28482 1/20 0.30
▸ CCNA1 P78396 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27630417 0.85 KDM4E (0.33) KDM4EALDH1A1HPGDADRA1AHSD17B10
SCHEMBL8369323 0.76 KDM4E (0.55) KDM4EALDH1A1HPGDADRA1AHSD17B10
SCHEMBL6151952 0.73 KDM4E (0.59) KDM4EALDH1A1HPGDADRA1AHSD17B10
SCHEMBL27630360 0.73 CDK5 (0.33) KDM4EALDH1A1HPGDADRA1AHSD17B10
SCHEMBL27725381 0.70 HSP90AA1 (0.39) KDM4EALDH1A1HPGDADRA1AHSD17B10
SCHEMBL28434898 0.63 KDM4E (0.54) KDM4EALDH1A1HPGDADRA1AHSD17B10
SCHEMBL9584563 0.61 HDAC6 (0.41) CDK1CDK2PRKACACCNA2PRKACG
SCHEMBL24790521 0.60 CDK1 (0.44) KDM4EALDH1A1HPGDADRA1AHSD17B10
SCHEMBL10922755 0.59 HSP90AB1 (0.43) KDM4EALDH1A1HPGDADRA1AHSD17B10
SCHEMBL27620345 0.59 CDK1 (0.46) KDM4EALDH1A1HPGDADRA1AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040266795-A1 Process for the preparation of famciclovir TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2004-12-30 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040266795-A1 Process for the preparation of famciclovir ADH1C, CPS1, PAICS KDM4E 114/4885ALDH1A1 186/4885HPGD 3258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback